Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.
Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older
January 14, 2022
September 22, 2021
Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials
June 23, 2021
Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity
March 30, 2021
Search Result :-Is an investigational new drug that has not been approved for commercial distribution in the United States.
US Media Contact
For media inquiries only, please contact Corporate Communications.
For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.